Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease

Abstract

Alzheimer’s disease (AD) is a complex neurodegenerative disorder with a multi-faceted pathogenesis. So far, the therapeutic paradigm “one-compound-one-target” has failed and despite enormous efforts to elucidate the pathophysiology of AD, the disease is still incurable. The multiple factors involved in AD include amyloid aggregation to form insoluble neurotoxic plaques of Aβ, hyperphosphorylation of tau protein, oxidative stress, calcium imbalance, mitochondrial dysfunction and deterioration of synaptic transmission. These factors together, accentuate changes in the CNS homeostasis, starting a complex process of interconnected physiological damage, leading to cognitive and memory impairment and neuronal death. A recent approach for the rational design of new drug candidates, also called multitarget-directed ligand (MTDL) approach, has gained increasing attention by many research groups, which have developed a variety of hybrid compounds acting simultaneously on diverse biological targets. This review aims to show some recent advances and examples of the exploitation of MTDL approach in the rational design of novel drug candidate prototypes for the treatment of AD.

Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer’s Disease

“…The pathogenesis in AD is frequently described as multifactorial, and such a notion is consistent with the relatively modest benefits from the targeted therapeutic agents [151, 152]. To address this issue, the scientific community may need to design, synthesize, and examine therapeutic agents with multi-target potential rather than single target drugs.…”

Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights

“…Quinones are considered as privileged structures and are among the most important drugs used against cancer [3]. Although single-target drugs successfully inhibit or activate a specific target [4], drugs that are able to act simultaneously on diverse biological targets are more attractive in the design of new effective drugs [5]. In this context, quinoidal structures represent an essential multi-target class of compounds [6].…”

Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment

“…In this context, the concept of multitarget drugs having an integrated action on a number of biological targets involved in pathogenesis of the disease currently appears to be highly promising in the design of drugs for treating AD678. It can be expected that these drugs would be able not only to compensate or restore the lost cognitive functions, but also to suppress further development of the neurodegenerative process9101112.…”